

ANNOUNCEMENT

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR TO U.S. PERSONS (AS DEFINED IN REGULATION S UNDER THE U.S. SECURITIES ACT OF 1933, AS AMENDED).

This announcement is not a solicitation of consent with respect to the Bonds (as defined below). The Consent Solicitation (as defined below) is being made solely pursuant to the Consent Solicitation Statement (as defined below) and related documents which set forth the complete terms of the Consent Solicitation.

This announcement and any materials relating to the Consent Solicitation do not constitute, and may not be used in connection with, any form of offer or solicitation in any place where such offers or solicitations are not permitted by law.

The distribution of this announcement in certain jurisdictions may be restricted by law. Persons into whose possession this announcement comes are required to inform themselves about, and to observe, any such restrictions.

CONSENT SOLICITATION EXERCISE BY FULLERTON HEALTH CORPORATION LIMITED (FORMERLY KNOWN AS FULLERTON HEALTHCARE CORPORATION LIMITED) (THE "COMPANY") IN CONNECTION WITH ITS S\$50,000,000 2.75 PER CENT. SENIOR UNSECURED GUARANTEED BONDS DUE 2023 (ISIN: SG73F0000002) (THE "BONDS") UNCONDITIONALLY AND IRREVOCABLY GUARANTEED BY CREDIT GUARANTEE AND INVESTMENT FACILITY, A TRUST FUND OF THE ASIAN DEVELOPMENT BANK

ANNOUNCEMENT OF RESULTS OF CONSENT SOLICITATION BY THE COMPANY IN CONNECTION WITH THE BONDS AS AT THE CONSENT DEADLINE

Shareholders of the Company who are not otherwise holders of the Bonds will not be eligible to attend or vote at the relevant Meeting either in person or by proxy.

The Company refers to the announcement made by the Company on 18 August 2022 in relation to the commencement of the consent solicitation exercise (the "**Consent Solicitation**") in connection with the Bonds.

Capitalised or other terms used but not defined herein shall, unless the context otherwise requires, have the meanings as set out in the consent solicitation statement dated 18 August 2022 (the "**Consent Solicitation Statement**") issued by the Company.

The Company wishes to announce that as at 9.00 a.m. (Singapore time) on 7 September 2022 (the "**Consent Deadline**"), holders of S\$47,750,000 in aggregate principal amount of the Bonds have submitted duly completed Proxy Forms to the CDP Meeting Agent to have their votes cast in favour of the Extraordinary Resolution at the Meeting, and no Bondholders have submitted duly completed Proxy Forms

to the CDP Meeting Agent to have their votes cast against the Extraordinary Resolution at the Meeting.

Based on the Voting Instructions received at the Consent Deadline, it is expected that the quorum required for the Meeting will be met and that the Extraordinary Resolution will be passed at the Meeting.

The Meeting will be held at 9.00 a.m. (Singapore time) on 9 September 2022 at the offices of the Consent Solicitation Agent at 30 Raffles Place, #04-01, Singapore 048622.

The Company will give notice of the results of the voting on the Extraordinary Resolution to Bondholders in accordance with Condition 15 (*Notices*) of the Conditions as soon as reasonably practicable after the conclusion of the Meeting (and in any event) no later than 14 days of such results being known but failure to do so shall not invalidate the Extraordinary Resolution.

Subject to the fulfilment of the Settlement Conditions, Bondholders who (i) submit or deliver, or arrange to have submitted or delivered on their behalf, valid and unrevoked Voting Instructions in favour of the Extraordinary Resolution to the CDP Meeting Agent, on or prior to the Consent Deadline, (being 9.00 a.m. (Singapore time) on 7 September 2022 or 48 hours before the time fixed for the adjourned Meeting, as applicable) or (ii) attend and vote in favour of the Extraordinary Resolution at the Meeting or, if applicable, any such adjourned Meeting, in respect of the Bonds shall be eligible to receive the Consent Fee.

Bondholders who (i) deliver Voting Instructions which are not in favour of the Extraordinary Resolution, (ii) deliver invalid Voting Instructions, (iii) deliver Voting Instructions after the Consent Deadline, or (iv) do not deliver Voting Instructions (where such Bondholders also do not attend and vote in favour of the Extraordinary Resolution at the Meeting or adjourned Meeting) will not be eligible to receive any Consent Fee.

For further information, please contact:

Fullerton Health Corporation Limited (formerly known as Fullerton Healthcare Corporation Limited)

c/o JustCo Marina Square
Suite S3110
6 Raffles Boulevard
#03-308 Marina Square
Singapore 039594

Attention: Chua Si Liang
Fax: +65 6672 5684
Email: siliang.chua@fullertonhealth.com

- END -

About Fullerton Health

Fullerton Health is a leading integrated health system in the Asia Pacific region. Founded in Singapore in 2010, today the Company serves clients through over 550 owned healthcare facilities and a large global network of healthcare providers across nine markets in Asia Pacific. Fullerton Health's value proposition is the integration of healthcare service offerings with customized management and advisory capabilities, in line with its purpose to deliver affordable and accessible care for all in Asia Pacific.



For more information on Fullerton Health, please visit <http://www.fullertonhealth.com/>

Disclaimer: This announcement or press release may contain forward-looking statements that involve risks and uncertainties. Actual future performance, outcomes and results may differ materially from those expressed in forward-looking statements as a result of a number of uncertainties, risks and assumptions. Representative examples of these factors include but are not limited to general market and economic conditions, interest rate trends, competition from other real estate investors, changes in operating expenses including employee wages and benefits, changes in government policies, and the continued availability of financing in the amounts and terms necessary to support future business. You are cautioned not to place undue reliance on any of the forward-looking statements in this announcement, which are based on the current view of management on future events.